BUZZ-Options traders brace for more pain at Valeant

** Options traders add to near-term bearish bets as Valeant
Pharmaceuticals International Inc's U.S.-listed shares
fall to 3-year low of $63.75 on Monday, on news that drugmaker
is under investigation by the U.S. SEC

** Valeant says it is subject of several ongoing
investigations, including the U.S. attorney's offices for
Massachusetts and New York, SEC